<DOC>
	<DOCNO>NCT01065727</DOCNO>
	<brief_summary>Cost-effectiveness study 2 disease-modifying therapy ( natalizumab versus mitoxantrone follow immunomodulator ) management aggressive remitting multiple sclerosis</brief_summary>
	<brief_title>Impact Study 2 Therapeutic Strategy Aggressive Remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>Patients remit multiple sclerosis accord mac Donald criterion aggressive remit multiple sclerosis accord follow criterion : 2 less disable relapse 12 month inclusion 1 EDSS 2 5 age less equal 40 year old woman effective contraception patient less 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Reemitting aggressive multiple sclerosis</keyword>
</DOC>